PRESS RELEASE published on 11/01/2024 at 18:18, 1 year 3 months ago Inside Information / Other news releases GenSight Biologics announces a €2.8 million financing through a Reserved Offering. Funding to extend cash runway for developing gene therapies. Details on investor support and future plans Investors Financing GenSight Biologics Gene Therapies Reserved Offering
BRIEF published on 10/24/2024 at 21:13, 1 year 3 months ago GenSight Biologics Discloses Cash Position, Advances on LUMEVOQ® Treasury Funding LUMEVOQ® ANSM Compassionate Access
PRESS RELEASE published on 10/24/2024 at 21:08, 1 year 3 months ago Inside Information / News release on accounts, results GenSight Biologics reports €3.4 million cash position as of September 30, 2024, updates on LUMEVOQ® drug product status, and financial discussions for future funding Cash Position Financial Update GenSight Biologics LUMEVOQ AAC Resumption
BRIEF published on 10/17/2024 at 07:35, 1 year 3 months ago GenSight Biologics Presents LUMEVOQ® Data at AAO 2024 Gene Therapy GenSight Biologics LUMEVOQ® LHON AAO 2024
PRESS RELEASE published on 10/17/2024 at 07:30, 1 year 3 months ago Inside Information / Other news releases GenSight Biologics to present scientific updates on LUMEVOQ® gene therapy at AAO 2024, including real-world experience and long-term outcomes for LHON patients Gene Therapy GenSight Biologics LHON LUMEVOQ AAO 2024
PRESS RELEASE published on 09/27/2024 at 11:24, 1 year 4 months ago HALF-YEAR_FINANCIAL_REPORT_JUNE_2024
BRIEF published on 09/23/2024 at 19:41, 1 year 4 months ago GenSight Biologics Reports Interim Financial Results for H1 2024 Financial Results Cash Management LUMEVOQ® Early Access Program R&D Expenses
PRESS RELEASE published on 09/23/2024 at 19:36, 1 year 4 months ago Inside Information / News release on accounts, results GenSight Biologics reports interim financial results for the first half of 2024, highlighting optimized cash management, extension of cash runway, and upcoming LUMEVOQ® drug product release Cash Management GenSight Biologics Interim Financial Results LUMEVOQ® Drug Product Release
BRIEF published on 09/17/2024 at 14:45, 1 year 4 months ago Goldman Sachs sells its GENSIGHT BIOLOGICS SA shares Euronext Paris Goldman Sachs Crossing Thresholds Transfer Of Shares GenSight Biologics
BRIEF published on 07/23/2024 at 07:35, 1 year 6 months ago GenSight Biologics Reports Financial Position and Business Progress Gene Therapy Financial Update GenSight Biologics LUMEVOQ Early Access Program
Published on 02/07/2026 at 01:00, 1 day 7 hours ago Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 9 hours ago Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 10 hours ago Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 16 hours ago Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 18 hours ago Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/07/2026 at 21:00, 11 hours 10 minutes ago Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 15 hours 35 minutes ago The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 15 hours 50 minutes ago NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 12 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 14 hours ago EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 18:22, 1 day 13 hours ago Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 16 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/05/2026 at 18:06, 2 days 14 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
